Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss.
By Christy Santhosh and Shashwat Chauhan Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its
On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock's biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.'s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (EL) rallied after the beauty company's adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views. - Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker's forecast sales for the second quarter missed the average analyst estimate.
Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors. In current studies, they are pairing it with Keytruda, a immunotherapy drug made by Merck.
By Julie Steenhuysen and Christy Santhosh CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a late-
Stock Market Today: The Dow Jones index rises Wednesday ahead of the Fed minutes. Nvidia supplier SK Hynix jumps on a stock buyback.
Shares of US vaccine-maker Moderna soared 60 per cent in pre-market trading after the company reported successful results for a melanoma cancer...
An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said. Shares in Moderna jumped about 10% premarket, while Merck also climbed around 6%.
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
It’s all about retail earnings this week with Walmart, Home Depot, Target and Alibaba all set to report.
What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.
On this episode of Stock Movers: - RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week. - Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround. - Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom.
Net loss improved 5% on international partnerships and manufacturing gains.
Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call
Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt
Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.
Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!
Shares in Moderna ticked higher after the biotech secured Food and Drug Administration approval for its mRNA flu vaccine for use in adults aged 50 and older. The FDA's decision capped an arduous seven-month process that included a rare refusal by the regulator to consider the shot.
Moderna (NASDAQ:MRNA) announced on Thursday that the U. S.
The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.
President Donald Trump discussed efforts to de-escalate US-Iran tensions with Qatari Emir Tamim bin Hamad Al Thani.
The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.
Moby summary of Moderna, Inc.'s Q2 2026 earnings call
Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
